Offner H, Celnik B, Bringman T S, Casentini-Borocz D, Nedwin G E, Vandenbark A A
Neuroimmunology Laboratory 151D-P, VA Medical Center, Portland, OR 97201.
J Neuroimmunol. 1990 Jul;28(2):177-84. doi: 10.1016/0165-5728(90)90032-i.
Human placental tissue contains regulatory molecules that may prevent allo-sensitization. Recently, a 14 kDa beta-galactoside binding protein with demonstrated immunoregulatory properties has been cloned using cDNA from human placenta and expressed in Escherichia coli. The present study assesses the ability of this recombinant immunomodulatory lectin (rIML-1), to prevent experimental autoimmune encephalomyelitis (EAE), a paralytic T cell-mediated disease directed against myelin basic protein (BP). Injection of rIML-1 into Lewis rats inhibited the induction of both clinical and histological signs of EAE, apparently by blocking sensitization of encephalitogenic BP-specific T cells and inducing BP-dependent suppressor cells. Because it is neither immunogenic nor toxic, rIML-1 may have application in humans, and would have distinct advantages over unselective cytotoxic immunosuppressive agents used currently in the treatment of autoimmune diseases and transplantation.
人胎盘组织含有可能防止同种致敏的调节分子。最近，利用人胎盘的cDNA克隆出一种具有免疫调节特性的14 kDaβ-半乳糖苷结合蛋白，并在大肠杆菌中表达。本研究评估了这种重组免疫调节凝集素（rIML-1）预防实验性自身免疫性脑脊髓炎（EAE）的能力，EAE是一种针对髓鞘碱性蛋白（BP）的麻痹性T细胞介导疾病。将rIML-1注射到Lewis大鼠体内可抑制EAE临床和组织学症状的诱导，显然是通过阻断致脑炎性BP特异性T细胞的致敏和诱导BP依赖性抑制细胞来实现的。由于rIML-1既无免疫原性也无毒性，它可能对人类有应用价值，并且相对于目前用于治疗自身免疫性疾病和移植的非选择性细胞毒性免疫抑制剂具有明显优势。
